
Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.
A key opinion leader reviews the case of a 71-year-old woman with NTRK gene fusion thyroid cancer and considers novel therapies available for the management of her disease.
Case: A 71-Year-Old Woman With Thyroid NTRK Gene Fusion Cancer
Initial Presentation
Clinical Workup and Initial Treatment
Follow-Up and Additional Treatment






